NEW YORK (Reuters) - Shares in generic drugmaker Mylan MYL.O could rise a further 20 percent over the next year, as more prescriptions outside of the U.S. are filled by generics, Barron's reported on Sunday.
Mylan, the world’s No. 3 generic drugmaker, could benefit as regulations change in the next few years to allow more prescriptions to be filled with generic drugs, the newspaper said.
The company may also get a boost as drugmakers lose key patents, Barron’s said. Mylan could this year win the right to produce drugs worth $800 million in annual revenue, Oppenheimer analyst John Newman told Barron’s.
Shares in Mylan closed up 1.11 percent at $19.07 on Friday. The company is due to report 2009 earnings on Thursday.
Reporting by Elinor Comlay; Editing Bernard Orr
Our Standards: The Thomson Reuters Trust Principles.